H3396 Xenograft Model Service for Breast Cancer

The H3396 xenograft model serves as a highly specialized in vivo platform for investigating the molecular drivers of HER2-amplified breast cancer and assessing the efficacy of targeted anti-tumor therapies. Alfa Cytology offers a premier H3396 xenograft model service, leveraging our deep expertise in oncology research to provide precise, high-fidelity data that streamlines your preclinical drug development process.

Overview of H3396 Xenograft Model for Breast Cancer

The H3396 cell line is a human mammary carcinoma model recognized for its significant HER2 (ERBB2) gene amplification and protein overexpression. Originally derived from a patient with metastatic breast cancer, this model has become a critical tool for researchers focused on HER2-positive oncology. Unlike some other HER2 models, H3396 cells exhibit a distinct growth profile and genetic background that make them particularly valuable for studying resistance mechanisms to standard-of-care treatments like Trastuzumab and Lapatinib.

When established in vivo as a xenograft, H3396 cells form stable, well-vascularized tumors in immunocompromised mice. The model faithfully recapitulates the histological and molecular characteristics of clinical HER2+ breast cancer, maintaining its aggressive proliferation and invasive potential.

Cell Line Information: H3396

The H3396 cell line is characterized by its epithelial morphology and potent tumorigenicity, providing a consistent foundation for both in vitro analysis and in vivo modeling.

Alfa Cytology is dedicated to upholding the highest standards of scientific integrity in every project. Our specialized technical team maintains a rigorously authenticated cell bank and employs optimized inoculation techniques to guarantee high tumor take rates and reproducible growth kinetics.

Our Services

Workflow of H3396 Xenograft Model Construction

Alfa Cytology follows a meticulously standardized and ethically compliant workflow to ensure the successful establishment of the H3396 xenograft model:

• Cell Preparation & Quality Control: H3396 cells are expanded in vitro under strictly controlled conditions. We perform comprehensive quality control, including STR profiling and mycoplasma testing, to ensure cell viability and phenotypic identity before inoculation.
• Host Selection: Healthy, standardized immunocompromised mice (such as Nude or SCID strains) are selected and allowed to acclimate to our controlled laboratory environment to ensure physiological stability.
• Standardized Inoculation: A precisely calibrated suspension of H3396 cells is prepared, often enhanced with a biological matrix carrier to ensure optimal in vivo engraftment. The injection is performed via subcutaneous or orthotopic routes.
• Longitudinal Monitoring: Following inoculation, we systematically monitor tumor dimensions and animal body weight using precision instruments. This allows us to establish a reliable growth curve and ensure the health of the animals throughout the study.
• Randomization & Grouping: Once tumors reach a consistent and statistically relevant volume, mice are randomized into treatment and control cohorts to ensure a balanced distribution and maximize the statistical power of the efficacy evaluation.

Fig 1. H3396 Xenograft Model Construction Workflow

Case Study - H3396 Xenograft Model Development

In a recent validation study conducted at Alfa Cytology, the H3396 xenograft model was utilized to evaluate the synergistic effects of a novel antibody-drug conjugate (ADC) combined with a kinase inhibitor. The model demonstrated exceptional tumor take and highly uniform growth kinetics, providing a clear window for therapeutic observation.

Why Choose Alfa Cytology?

• HER2 Specialization: Expert knowledge in establishing and characterizing HER2-amplified models.
• Technical Rigor: Proven inoculation protocols that ensure high take rates and reproducible growth.
• Advanced Readouts: Capability to perform integrated PK/PD analysis, IHC for HER2 expression, and endpoint pathology.
• Global Quality Standards: Commitment to ethical animal welfare and scientifically sound experimental designs.

Contact Us

Are you ready to accelerate your HER2+ breast cancer research with a high-performance H3396 xenograft model? Our senior scientists at Alfa Cytology are available to provide tailored experimental designs and technical insights to meet your drug discovery milestones. Please contact us directly to request a comprehensive quote for your in vivo research needs.

For research use only. Not intended for any clinical use.